Key result
Structured exercise fails to preserve LVEF or global longitudinal strain during cardiotoxic breast cancer therapy.
Why the study?
It is uncertain whether structured exercise preserves LVEF, GLS, and cardiac biomarkers in women with breast cancer receiving anthracyclines and/or anti-HER2 therapy.
Does structured exercise compared with usual care preserve LVEF, GLS, and cardiac biomarkers in women with breast cancer receiving anthracyclines and/or anti-HER2 therapy?
Meta-Analysis (n=513)
Does structured exercise compared with usual care preserve LVEF, GLS, and cardiac biomarkers in women with breast cancer receiving anthracyclines and/or anti-HER2 therapy?
Current randomized evidence is too sparse and heterogeneous to confirm a consistent cardioprotective effect of structured exercise on LVEF or GLS during anthracycline or anti-HER2 therapy in breast cancer.
Answers are grounded in this paper and cite their sources.
Does not support structured exercise for LVEF or GLS preservation during cardiotoxic therapy; leaves open benefit in larger, longer trials.
Purpose To evaluate whether structured exercise, compared with usual care, preserves left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), and cardiac biomarkers in women with breast cancer receiving anthracyclines and/or anti-HER2 therapy. Methods We performed a systematic review and meta-analysis of randomized controlled trials. Risk of bias was assessed with the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), and certainty of evidence with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. When clinically and methodologically comparable, effects were pooled as net differences in change (ΔEG − ΔCG) using random-effects models. The primary synthesis was restricted to the baseline-to-end-of-anthracycline-treatment window (~ 4 months). Results Seven trials (9 reports; n = 513) were included. Most trials had some concerns or high risk of bias. Quantitative synthesis was feasible in only two trials. No between-group differences were observed for LVEF (MD 0.07, 95% CI − 1.38 to 1.52; I2 = 28.2%) or GLS (MD − 0.10, 95% CI − 0.79 to 0.58; I2 = 0%). Confidence intervals were wide and compatible with benefit, no effect, or harm. Biomarker data were too heterogeneous for meta-analysis. Comparative clinical cardiovascular-event and survival outcomes and formal assessments of heart failure with preserved ejection fraction (HFpEF) were not reported. Conclusion Current randomized evidence is sparse, heterogeneous, and of low certainty. Available data do not confirm a consistent cardioprotective effect of exercise on LVEF or GLS and do not permit conclusions about clinical cardiovascular events, survival, or HFpEF.
No takes yet. Share an insight, caveat, or question.
Mielgo et al. (2026) conducted a meta-analysis in Breast cancer (n=513). Structured exercise vs. Usual care was evaluated on Left ventricular ejection fraction (LVEF) (MD 0.07, 95% CI -1.38 to 1.52). Structured exercise did not preserve left ventricular ejection fraction or global longitudinal strain compared to usual care in women with breast cancer receiving cardiotoxic therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: